From September 28 to 29, 2025, General Manager Jiao Mingming of Zhejiang Tianyuan Biotechnology Co., Ltd., Dr. Liu Guangcheng, Director of the Cell Laboratory, and the project lead for Hainan Tianyuan Bio (in preparation) undertook an intensive and highly productive visit to Hainan, aiming to accelerate the local implementation of Tianyuan Bio's cell industry. The itinerary covered comprehensive and in-depth inspections and project discussions at multiple key institutions and locations, including Hainan Medical University, the Affiliated Hospital of Hainan Medical University, the Hainan Provincial Drug Research and Development Science Park, the Haikou Bio-Industry Park, the Medicine Valley of Haikou National Hi-Tech Zone, and the Boao Lecheng International Medical Tourism Pilot Zone.

Visit and Inspection at Medicine Valley, Haikou National Hi-Tech Zone

Visit and Inspection at Hainan Provincial Drug Research and Development Science Park

      During the meeting on September 28 with Hainan Medical University and its First Affiliated Hospital, core team members from both sides were fully present. The university was represented by Vice President Jia Bin and Yang Xiaobo, Chairman of the University's State-owned Asset Management Company, while the First Affiliated Hospital was represented by Vice President Huang Xionggao and Wang Ziqiang, Director of the Scientific Research Department, among others.

      Preliminary discussions centered on the implementation of new cell therapy technologies. Leveraging its domestically leading iPS artificially induced pluripotent stem cell technology, extensive industry-academia integration experience, and advanced cell culture techniques, Tianyuan Bio aims to collaborate with Hainan Medical University and its First Affiliated Hospital. By capitalizing on the pioneering policies of the Boao Lecheng "Medical Special Zone" in Hainan, the parties strive to achieve breakthroughs in the field of cell therapy and seize early development opportunities.

      On September 29, Tianyuan Bio held further in-depth exchanges with the expert team from the First Affiliated Hospital of Hainan Medical University. Both sides engaged in detailed discussions on specific scientific research collaboration projects, with participation from hospital leadership and experts from the Scientific Research Department, Clinical Trial Department, Orthopedics, Pediatrics, Infectious Diseases, Reproductive Medicine, and other departments, jointly contributing ideas to promote the clinical application of cell therapy technologies.

      These exchanges mark the entry of Tianyuan Bio's cell industry layout in Hainan into a substantive phase. They have not only strengthened ties with local medical institutions and research units but also laid a solid foundation for future cooperation. Through strategic initiatives such as the construction of an iPS seed cell bank and the application for cell therapy technology approvals, Tianyuan Bio will fully leverage its technological advantages, seize Hainan's policy opportunities, promote the clinical application and industrial development of cell therapy technologies in Hainan, inject new vitality into Hainan's biomedical industry, and explore new growth space for its own development.

 
      This inspection tour to Hainan represents a critical step for Tianyuan Bio in expanding its footprint and deepening its industrial layout. Adhering to a philosophy of open cooperation, the company actively integrates resources from all parties and is committed to bringing advanced cell therapy technologies to benefit more patients, thereby contributing to China's life and health industry.

Zhejiang Tianyuan Biotechnology Co., Ltd., founded in 2017, is a national high-tech enterprise dedicated to cell research, development, production, operation, and service. It possesses valuable resource banks including an HLA Umbilical Cord Matching Library, iPS Seed Cell Bank, and Cancer Cell Bank. The company is the drafting unit for the National Health Commission's association standard on immune function assessment methods. In collaboration with the National Health Commission's Research Institute, it has co-established a Joint Laboratory for Metabolic Immunity Monitoring. Furthermore, it serves as important research and service platforms, including the Ningbo Storage Center of the National Stem Cell Transformation Resource Bank and the Achievement Transformation Center of the National Health Commission's Research Institute.